These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 15200734)
1. Direct medical costs associated with using vancomycin in methicillin-resistant Staphylococcus aureus infections: an economic model. Shah NP; Reddy P; Paladino JA; McKinnon PS; Klepser ME; Pashos CL Curr Med Res Opin; 2004 Jun; 20(6):779-90. PubMed ID: 15200734 [TBL] [Abstract][Full Text] [Related]
2. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections. McKinnon PS; Sorensen SV; Liu LZ; Itani KM Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705 [TBL] [Abstract][Full Text] [Related]
3. Outcomes and costs associated with a history of vancomycin exposure in patients with MRSA-related complicated bacteremia and infective endocarditis. Brown J; Brown KA; Forrest A Clin Ther; 2011 Oct; 33(10):1475-82. PubMed ID: 21925733 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesis. Bounthavong M; Zargarzadeh A; Hsu DI; Vanness DJ Value Health; 2011; 14(5):631-9. PubMed ID: 21839399 [TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of daptomycin versus vancomycin and gentamicin for patients with methicillin-resistant Staphylococcus aureus bacteremia and/or endocarditis. Bhavnani SM; Prakhya A; Hammel JP; Ambrose PG Clin Infect Dis; 2009 Sep; 49(5):691-8. PubMed ID: 19635023 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of linezolid and vancomycin in the treatment of surgical site infections. Patanwala AE; Erstad BL; Nix DE Curr Med Res Opin; 2007 Jan; 23(1):185-93. PubMed ID: 17257479 [TBL] [Abstract][Full Text] [Related]
7. Impact of methicillin-resistant Staphylococcus aureus infections on key health economic outcomes: does reducing the length of hospital stay matter? Nathwani D J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii37-44. PubMed ID: 12730141 [TBL] [Abstract][Full Text] [Related]
8. [Pharmacoeconomic analysis of the treatment of methicillin-resistant Staphylococcus aureus with daptomycin or vancomycin]. Rubio-Terrés C; Rubio-Rodríguez D; Majos N; Grau S Rev Esp Quimioter; 2012 Dec; 25(4):283-92. PubMed ID: 23303261 [TBL] [Abstract][Full Text] [Related]
9. A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aureus in elderly US patients. McCollum M; Sorensen SV; Liu LZ Clin Ther; 2007 Mar; 29(3):469-77. PubMed ID: 17577468 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of linezolid vs. vancomycin in treating methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections using a decision analytic model. Bounthavong M; Hsu DI; Okamoto MP Int J Clin Pract; 2009 Mar; 63(3):376-86. PubMed ID: 19222624 [TBL] [Abstract][Full Text] [Related]
11. Cost analysis of switching from i.v. vancomycin to p.o. linezolid for the management of methicillin-resistant Staphylococcus species. McCollum M; Rhew DC; Parodi S Clin Ther; 2003 Dec; 25(12):3173-89. PubMed ID: 14749155 [TBL] [Abstract][Full Text] [Related]
12. Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. Patel DA; Shorr AF; Chastre J; Niederman M; Simor A; Stephens JM; Charbonneau C; Gao X; Nathwani D Crit Care; 2014 Jul; 18(4):R157. PubMed ID: 25053453 [TBL] [Abstract][Full Text] [Related]
13. Economic evaluation among Chinese patients with nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus and treated with linezolid or vancomycin: a secondary, post-hoc analysis based on a Phase 4 clinical trial study. Wan Y; Li Q; Chen Y; Haider S; Liu S; Gao X J Med Econ; 2016; 19(1):53-62. PubMed ID: 26490296 [TBL] [Abstract][Full Text] [Related]
14. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Sharpe JN; Shively EH; Polk HC Am J Surg; 2005 Apr; 189(4):425-8. PubMed ID: 15820454 [TBL] [Abstract][Full Text] [Related]
15. Use of Oritavancin in Acute Bacterial Skin and Skin Structure Infections Patients Receiving Intravenous Antibiotics: A US Hospital Budget Impact Analysis. Jensen IS; Lodise TP; Fan W; Wu C; Cyr PL; Nicolau DP; DuFour S; Sulham KA Clin Drug Investig; 2016 Feb; 36(2):157-68. PubMed ID: 26692006 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin structure infections. Laohavaleeson S; Barriere SL; Nicolau DP; Kuti JL Pharmacotherapy; 2008 Dec; 28(12):1471-82. PubMed ID: 19025428 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany. Schürmann D; Sorensen SV; De Cock E; Duttagupta S; Resch A Eur J Health Econ; 2009 Feb; 10(1):65-79. PubMed ID: 18437437 [TBL] [Abstract][Full Text] [Related]
18. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid. Stein GE; Wells EM Curr Med Res Opin; 2010 Mar; 26(3):571-88. PubMed ID: 20055750 [TBL] [Abstract][Full Text] [Related]
19. Health economics assessment study of teicoplanin versus vancomycin in Gram-positive infections. Portolés A; Palau E; Puerro M; Vargas E; Picazo JJ Rev Esp Quimioter; 2006 Mar; 19(1):65-75. PubMed ID: 16688294 [TBL] [Abstract][Full Text] [Related]
20. Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin. Shorr AF; Susla GM; Kollef MH Crit Care Med; 2004 Jan; 32(1):137-43. PubMed ID: 14707572 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]